Penumbra, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 3:30 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 3:30 PM EDT. The presentation will be available via webcast through the company’s investor section on its website, accessible for two weeks post-event. Based in Alameda, California, Penumbra focuses on innovative therapies across healthcare, targeting significant medical needs and selling products mainly in the U.S., Europe, Canada, and Australia.
Details
News Market Reaction – PEN
The recorded move for PEN in the trading session of this news was +1.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., July 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020.
Event: Canaccord Genuity 40th Annual Growth Conference
Date: Wednesday, August 12, 2020
Time: 3:30pm EDT / 12:30pm PDT
A webcast of the presentation will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/penumbra-inc-to-present-at-the-canaccord-genuity-40th-annual-growth-conference-301100580.html
SOURCE Penumbra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.